​Spotlight Report: Eledon Pharmaceuticals

May 5, 2026

Since the beginning of the year, Eledon Pharmaceuticals has received significant media attention, and its stock price has risen dramatically as a result, up +149%. Its lead product, tegoprubart, posted early success in human clinical trials, prompting discussion in the T1D community about its potential as the key to a cure.

This report will provide an overview of tegoprubart and the company developing it. We will break down how tegoprubart works, evaluate its potential role in delivering a T1D Practical Cure, and summarize the company’s financial position.

Company Background

Eledon Pharmaceuticals is a biotechnology company headquartered in Irvine, California. Its sole product is tegoprubart, which is being explored for use in five different disease areas, including T1D, ALS, and various forms of allo (from another human) and xeno (from an animal) transplantation.

The company was founded in 2004 as Tokai Pharmaceuticals with a focus on prostate cancer and has undergone many changes since then. In 2017, the company merged with Otic Pharma, adopting its ear, nose, and throat disorders pipeline under the name Novus Therapeutics. After acquiring Anelixis Therapeutics in 2021, the company underwent its final evolution to focus solely on tegoprubart. The company formally changed its name to Eledon in 2022.

Eldon is a public company trading under the ticker ELDN on Nasdaq with a market cap of $301 million. As of May 4, the mid-day stock price was $3.78.

What Is Tegoprubart?

Tegoprubart is a therapy that intends to stop the immune attack that destroys transplanted tissues and organs. It is a monoclonal antibody (lab-made protein) that targets and blocks the CD40 cell communication pathway, stopping the signal that triggers T cells to attack. It also boosts Treg generation, ‘good’ T cells that help prevent autoimmune reactions.

It is being investigated as a safer, less toxic immune-suppressing treatment to protect transplanted organs (and beta cells) than commonly used alternatives. The lower toxicity should reduce substantial side effects, including cancer, infection, and organ stress (including damage to transplanted organs), that are common after transplant procedures that rely on traditional immunosuppressants.

For T1D, Eledon is developing tegoprubart as the core component of an immunosuppressive regimen to protect transplanted insulin-producing islet cells. In the current active trial, tegoprubart replaces tacrolimus, a potent immunosuppressant that suppresses the entire immune system and is highly toxic. Eledon says that tegoprubart, unlike tacrolimus, does not affect the cells that serve as the first line of defense against common infections and pathogens.

However, tegoprubart does impact the immune system beyond just stopping the attack on beta cells, though to what degree is unknown. This is not a purely local therapy that only targets immune cells involved in the beta cell attack. It is still an immunosuppressant that impacts a wide range of immune functions.

Clinical Trial Early Results

Tegoprubart is currently being tested in a phase I/II clinical trial led by the University of Chicago. The main purpose of the trial is to test tegoprubart as a replacement for tacrolimus in traditional islet cell transplantation. A few key characteristics of the trial:

• Cells used in the trial are sourced from cadavers.
• Participants are adults with brittle T1D experiencing extreme fluctuations in blood sugar.
• Additional antirejection drugs are given during the first few weeks to protect the transplanted cells from initial rejection (Basiliximab and Etanercept).
• Tegoprubart and a systemic immunosuppressant (CellCept) are given via a fifteen-minute IV once every three weeks as long-term maintenance. This will need to be repeated for perpetuity.

Interim trial results were published on March 16^th, stating that 100% of patients (10) were insulin independent after four weeks post-transplant. All reported HbA1cs <6%.

Adverse events reported were minor.

Is This on the Path to a Practical Cure?

Tegoprubart, in its current use, is not a Practical Cure for T1D.

The current trial uses full-body immunosuppressants and cadaveric cells. Cadaveric cells are unscalable, with a very minimal supply that limits islet transplantation to only those with brittle cases of T1D. In its current testing format, tegoprubart is distinctly not the key to expanding islet transplantation as a treatment for the vast majority of people living with T1D.

However, based on early results, it seems to offer a real improvement for the small number of individuals with brittle T1D and access to the therapy. For those who are good candidates for a cadaveric islet cell transplantation, a less toxic immune suppression regimen is a great step forward.

In our view, the recent excitement for tegoprubart is out of proportion with its current use case.

Collaborations and Partnerships

The company is currently involved in two collaborations testing tegoprubart as cell protection. Both are led by the noted companies.

Sernova Biotherapeutics (July 2025):

• Tegoprubart is being tested along with the Sernova Cell Pouch in a Phase I/II trial. No results yet posted.

NewcelX (March 2026):

• Tegoprubart will be tested with NewcelX’s stem cell-derived beta cell product, NCEL-101.
• IND for the first clinical trial testing NCEL-101 is targeted for Q1 2027.

Financial Highlights

Since the beginning of the year, the positive news about tegoprubart has given Eledon a remarkable boost in its stock price and market cap, unlike any in its history. The stock is up +149%. The market seems to expect big things from Eledon.

Eledon is a small entrepreneurial company with about thirty-five employees. It has a market cap of $301 million and a price-to-book ratio of 2.03, suggesting it could be trading at an attractive level. The stock price, at $3.78 as of publication, is a penny stock with the risk of large, short-term fluctuations.

Today, the company does not have a revenue-generating product. It has acquired its operating capital through grants, collaborations, investors, and investigator-led trials. Funding has come primarily from Breakthrough T1D grants, a T1D Fund equity investment, The Cure Alliance, and Sanofi Ventures.

Operating capital will remain a key challenge for Eledon as it continues to develop tegoprubart. The company ended 2025 with $133 million in cash and cash equivalents and short-term investments. Based on current operating plans, the company believes it can fund its operations for the next twelve months, but will require additional financing to fund subsequent years.


Future Potential

The key to growth for tegoprubart is to find a market that allows scale. The current use case being tested for T1D is hamstrung by the limited supply and high cost of cadaveric islets. To scale up within T1D, tegoprubart must prove that it can be used as a part of a therapy that can reach many people with T1D rather than only the most brittle. One pathway to a wider market is if tegoprubart proves itself capable of protecting stem cell-derived beta cells, which can be produced at scale. However, this is a future prospect, and collaborations testing with this cell type have not yet initiated clinical trials.

The other avenue for growth, perhaps more compelling from a financial lens, is outside of T1D. If tegoprubart can replace tacrolimus more broadly in general transplantation, it will find a large market. Last year, tacrolimus generated an estimated $7.3 billion in sales. If tegoprubart is approved for the same indications, Eledon’s stands to overtake a significant portion, or at least some, of that revenue.
 
 
Disclaimer
Please note that any and all assessments held within this report are not intended to convey a Buy/Sell/Hold rating and are neither financial advice nor encouraging investments in specific companies. The intention of this report is to serve as a public service to the T1D community by introducing companies impacting T1D today. It is not intended as the basis of financial decisions.